Synovo — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Synovo GmbH is a private, pre-clinical stage biotechnology company leveraging its interdisciplinary expertise in pharmacology, medicinal chemistry, and bioanalytics. The company pursues a hybrid strategy, generating revenue through contract research services while advancing an internal pipeline targeting inflammation and innate immunity. With a team of nearly 50 specialists and a strong network of global research partners, Synovo aims to translate scientific insight into novel therapeutic options for unmet medical needs.

InflammationInnate Immunity

Technology Platform

Integrated interdisciplinary drug discovery engine combining medicinal chemistry, pharmacology, and bioanalytics, with a focus on mechanistic insight and biomarker discovery.

Opportunities

The large and growing market for inflammation therapeutics and drug discovery services provides a dual growth path.

Developing companion diagnostics alongside therapeutics could enable a precision medicine approach, increasing clinical success rates and commercial value.

Risk Factors

High failure risk of early-stage internal drug programs and intense competition in both the contract research and inflammation therapeutic markets.

Balancing resource allocation between revenue-generating services and internal R&D is a persistent strategic challenge.

Competitive Landscape

Competes with large global CROs and niche discovery boutiques in the service sector. In therapeutic development, faces numerous well-funded biopharma companies targeting inflammation and immunity. Differentiation relies on deep integrated expertise and a focus on innate immune processes.

More companies in Small Molecule Drugs →More companies in Germany →